Provided by Tiger Trade Technology Pte. Ltd.

VanEck Biotech ETF

231.93
+2.541.11%
Volume:4K
Turnover:858.24K
Market Cap:465.37M
PE:- -
High:232.09
Open:229.59
Low:229.59
Close:229.39
52wk High:244.35
52wk Low:160.91
Shares:2.01M
Float Shares:2.01M
Volume Ratio:0.49
T/O Rate:0.19%
Dividend:0.96
Dividend Rate:0.42%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets

TIPRANKS
·
Aug 28

Revolution Medicines' Rasonque Label Expands Commercial Opportunity, Oppenheimer Says

MT Newswires Live
·
Aug 28

Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Amgen (AMGN)

TIPRANKS
·
Aug 27

HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million

Reuters
·
Aug 27

Street View: Revolution's Pancreatic Cancer Drug Nod Sparks a 'transformative' Era

Reuters
·
Aug 27

Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements

TIPRANKS
·
Aug 27

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Immuneering (IMRX)

TIPRANKS
·
Aug 27

China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales

Reuters
·
Aug 27

JW Cayman Therapeutics FY26 H1 IFRS Loss Narrows 81.14% to RMB 50.4 Million; Revenue Rises 4.7% to RMB 111.4 Million

Reuters
·
Aug 27

Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints

TIPRANKS
·
Aug 27

AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients

MT Newswires Live
·
Aug 27

Vertex Corp. Added to JPX-Nikkei Mid and Small Cap Index for FY2026

TIPRANKS
·
Aug 27

Vertex Corp. Refines Leadership Structure at Key Subsidiary Vertex Co.

TIPRANKS
·
Aug 27

AstraZeneca-Amgen Asthma Drug Succeeds in Late-Stage Oesophagus Disease Trial

Reuters
·
Aug 27

Amgen - Tezspire Safety Profile Consistent with Approved Indications

THOMSON REUTERS
·
Aug 27

Tezspire® Demonstrates Positive Phase 3 Results in Eosinophilic Esophagitis Across Both Co-Primary and All Key Secondary Endpoints

THOMSON REUTERS
·
Aug 27

Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $260 from $230

THOMSON REUTERS
·
Aug 27

Moderna Inc. Stock Falls 5.8%, Underperforms Peers

Dow Jones
·
Aug 27

Gilead Sciences Updates Financial Calendar with Investor Conference Presentations

Reuters
·
Aug 27

Vertex to Present at Wells Fargo Healthcare Investor Conference Fireside Chat

Reuters
·
Aug 27